Skip to main content
Clinical Trials/NCT00370370
NCT00370370
Unknown
Phase 3

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Shahid Beheshti University of Medical Sciences1 site in 1 countryNovember 2005

Overview

Phase
Phase 3
Intervention
bevacizumab
Conditions
Neovascular Age-Related Macular Degeneration
Sponsor
Shahid Beheshti University of Medical Sciences
Locations
1
Primary Endpoint
visual acuity
Last Updated
17 years ago

Overview

Brief Summary

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Registry
clinicaltrials.gov
Start Date
November 2005
End Date
TBD
Last Updated
17 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria

  • History of glaucoma or ocular hypertension
  • Disciform scar

Arms & Interventions

1

Injection of intravitreal bevacizumab

Intervention: bevacizumab

2

Injection of bevacizumab + triamcinolone acetonide

Intervention: bevacizumab + triamcinolone acetonide

Outcomes

Primary Outcomes

visual acuity

Secondary Outcomes

  • leakage in fluorescein angiography
  • intraocular pressure
  • anterior chamber reaction
  • central macular thickness

Study Sites (1)

Loading locations...

Similar Trials